Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis.

Conclusions: Rh-endostatin combined chemotherapeutic agents significantly improved clinical efficacy compared with chemotherapeutic agents alone in treating bone and soft tissue sarcomas. Moreover, combination of rh-endostatin with chemotherapy didn't increase the incidence of AEs. But more high quality RCTs with  large  sample  size  should  be  done  in  the  future  to confirm the conclusion.
PMID: 30352660 [PubMed - in process]

Source: J Pharm Pharm Sci - October 26, 2018 Category: Drugs & Pharmacology Authors: Ma Z, Guo L, Cui X, Liu H, Liu L Tags: J Pharm Pharm Sci Source Type: research